Pembrolizumab-Induced Vitiligo in Esophageal Squamous Cell Carcinoma Patient With Durable Complete Response

被引：7

作者：

Wilkins, Matthew C. ^{[1
]}

Elgamal, Mohamed ^{[2
]}

Rybkin, Igor I. ^{[1
]}

机构：

[1] Henry Ford Hlth Syst, Hematol & Oncol, Detroit, MI 48202 USA

[2] Henry Ford Hlth Syst, Hematol & Med Oncol, Detroit, MI USA

来源：

CUREUS JOURNAL OF MEDICAL SCIENCE | 2021年 / 13卷 / 11期

关键词：

medical oncology; gastrointestinal oncology; oncology; clinical dermatology; dermatology; vitiligo; pembrolizumab; adverse drug events; esophageal squamous cell carcinoma (sec); cancer immunotherapy; ASSOCIATION; IRINOTECAN;

D O I：

10.7759/cureus.19739

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Immune checkpoint inhibitors have emerged as a valuable therapeutic strategy in cancer treatment. Pembrolizumab is an inhibitor of programmed cell death protein 1 (PD-1) and its ligands 1 (PD-L1) and 2 (PD-L2). Disrupting the interaction between PD-LI expressed on the cancer cell and PD-1 transmembrane protein on immune cells results in reactivation of T cell-mediated cellular immunity. This immune modulation has increased the risk of autoimmune adverse events, which can affect any organ system. Here, we present a case of delayed immune checkpoint inhibitor-induced vitiligo in a 74-year-old female with recurrent metastatic esophageal carcinoma who remains in remission more than five years after initiation of pembrolizumah.

引用

页数：7

共 12 条

[1] Cutaneous Events Associated with Immunotherapy of Melanoma: A Review [J].

Burzi, Lorenza ;

Alessandrini, Aurora Maria ;

Quaglino, Pietro ;

Piraccini, Bianca Maria ;

Dika, Emi ;

Ribero, Simone .

JOURNAL OF CLINICAL MEDICINE, 2021, 10 (14)

[2] Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer Phase 2 Clinical KEYNOTE-059 Trial [J].

Fuchs, Charles S. ;

Doi, Toshihiko ;

Jang, Raymond W. ;

Muro, Kei ;

Satoh, Taroh ;

Machado, Manuela ;

Sun, Weijing ;

Jalal, Shadia I. ;

Shah, Manish A. ;

Metges, Jean-Phillipe ;

Garrido, Marcelo ;

Golan, Talia ;

Mandala, Mario ;

Wainberg, Zev A. ;

Catenacci, Daniel V. ;

Ohtsu, Atsushi ;

Shitara, Kohei ;

Geva, Ravit ;

Bleeker, Jonathan ;

Ko, Andrew H. ;

Ku, Geoffrey ;

Philip, Philip ;

Enzinger, Peter C. ;

Bang, Yung-Jue ;

Levitan, Diane ;

Wang, Jiangdian ;

Rosales, Minori ;

Dalal, Rita P. ;

Yoon, Harry H. .

JAMA ONCOLOGY, 2018, 4 (05)

[3] Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: A randomised phase III trial (TCOG GI-0801/BIRIP trial) [J].

Higuchi, Katsuhiko ;

Tanabe, Satoshi ;

Shimada, Ken ;

Hosaka, Hisashi ;

Sasaki, Eisaku ;

Nakayama, Norisuke ;

Takeda, Yuiti ;

Moriwaki, Toshikazu ;

Amagai, Kenji ;

Sekikawa, Takashi ;

Sakuyama, Toshikazu ;

Kanda, Tatsuo ;

Sasaki, Tohru ;

Azuma, Mizutomo ;

Takahashi, Fumiaki ;

Takeuchi, Masahiro ;

Koizumi, Wasaburo .

EUROPEAN JOURNAL OF CANCER, 2014, 50 (08) :1437-1445

[4] Time-Dependent Measurement of Adverse Events [J].

Hwang, Shelley Ji Eun ;

Byth, Karen ;

Fernandez-Penas, Pablo .

JAMA DERMATOLOGY, 2015, 151 (12) :1392-1392

[5] Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma [J].

Joshi, Smita S. ;

Maron, Steven B. ;

Catenacci, Daniel V. .

FUTURE ONCOLOGY, 2018, 14 (05) :417-430

[6] Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-)181 study. [J].

Kojima, Takashi ;

Muro, Kei ;

Francois, Eric ;

Hsu, Chih-Hung ;

Moriwaki, Toshikazu ;

Kim, Sung-Bae ;

Lee, Se-Hoon ;

Bennouna, Jaafar ;

Kato, Ken ;

Lin, Shen ;

Qin, Shi-Qui ;

Ferreira, Paula ;

Doi, Toshihiko ;

Adenis, Antoine ;

Enzinger, Peter C. ;

Shah, Manish A. ;

Wang, Ruixue ;

Bhagia, Pooja ;

Kang, S. Peter ;

Metges, Jean-Philippe .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)

[7] Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial [J].

Muro, Kei ;

Chung, Hyun Cheol ;

Shankaran, Veena ;

Geva, Ravit ;

Catenacci, Daniel ;

Gupta, Shilpa ;

Eder, Joseph Paul ;

Golan, Talia ;

Le, Dung T. ;

Burtness, Barbara ;

McRee, Autumn J. ;

Lin, Chia-Chi ;

Pathiraja, Kumudu ;

Lunceford, Jared ;

Emancipator, Kenneth ;

Juco, Jonathan ;

Koshiji, Minori ;

Bang, Yung-Jue .

LANCET ONCOLOGY, 2016, 17 (06) :717-726

[8] Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression [J].

Sanlorenzo, Martina ;

Vujic, Igor ;

Daud, Adil ;

Algazi, Alain ;

Gubens, Matthew ;

Luna, Sara Alcantara ;

Lin, Kevin ;

Quaglino, Pietro ;

Rappersberger, Klemens ;

Ortiz-Urda, Susana .

JAMA DERMATOLOGY, 2015, 151 (11) :1206-1212

[9] Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus The Phase 2 KEYNOTE-180 Study [J].

Shah, Manish A. ;

Kojima, Takashi ;

Hochhauser, Daniel ;

Enzinger, Peter ;

Raimbourg, Judith ;

Hollebecque, Antoine ;

Lordick, Florian ;

Kim, Sung-Bae ;

Tajika, Masahiro ;

Kim, Heung Tae ;

Lockhart, A. Craig ;

Arkenau, Hendrik-Tobias ;

El-Hajbi, Farid ;

Gupta, Mukul ;

Pfeiffer, Per ;

Liu, Qi ;

Lunceford, Jared ;

Kang, S. Peter ;

Bhagia, Pooja ;

Kato, Ken .

JAMA ONCOLOGY, 2019, 5 (04) :546-550

[10]

Surveillance Epidemiology and End Results (SEER) Program., 2021, CANC STAT FACTS ES C

← 1 2 →